ArticleThe Lancet regional health. Europe2024

SGLT2 inhibitors for patients with type 2 diabetes mellitus after myocardial infarction: a nationwide observation registry study from SWEDEHEART.

Hans Christian Rosén et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.